News

Posted On: 12/20/2005

Baxter Appoints VP of Global Regulatory Affairs and Medical Vigilance

PharmaManufacturing.com

Baxter International Inc. (Deerfield, Ill.) on Dec. 20 announced the appointment of Steven Caffe, M.D., to the position of vice president, global regulatory affairs and medical vigilance. He will report to Norbert Riedel, Baxter's chief scientific officer, and will be responsible for the company's regulatory and medical vigilance matters on a global basis. The appointment is effective Jan. 3, 2006.

"Steve brings top industry experience, clinical expertise and an in-depth understanding of regulatory affairs to this role at Baxter," said Riedel. "He also has a strong track record in the successful development and approval of several new chemical entities both in the United States and abroad."

Prior to joining Baxter, Caffe served as U.S. deputy head of regulatory development at Sanofi-Aventis.

Caffe started his industry career in clinical research at Laboratoires Delalande and Parke-Davis in France, a role in which he managed pan-European clinical trials. In 1992 he joined Merck & Co. in West Point, Pa., as associate director of international regulatory affairs. In 1999 Caffe was promoted to senior director of domestic regulatory affairs.

In 2001 Caffe joined Aventis Pharmaceuticals as vice president and head of the company's U.S. regulatory liaison group, remaining with Sanofi-Aventis until December 2005.

Caffe practiced medicine at the academic hospitals of Assistance Publique de Paris where he had previously completed his internship and residency in internal medicine. He earned his M.D. degree from the Universite Pierre et Marie Curie in Paris, France.